Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)

Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) is a phase 2/3, randomised interventional study registered as NCT06958419 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 286 participants, started 2025-05-01 and due to reach its primary completion in 2030-12-31. Interventions recorded: Node-Sparing Radiotherapy plus first-line therapy; First-line treatment. Conditions listed: Immune Checkpoint Therapy; Radiotherapy; Metastatic Colorectal Cancer (CRC). Primary outcome: Objective Response Rate(ORR); Progression-free survival (PFS). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.